China Biologic Products, Inc. (CBPO.OB) Appoints Director of Research and Development

By @ibtimes on

China Biologic Products, Inc. has been gaining a reputation as one of the leading plasma-based pharmaceutical companies in the People’s Republic of China and has obtained great success operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. and Chongging Dalin Biologic Technologies Co. While the young company has been making strides across the globe, they obtained a major asset to their company with the announcement that they have appointed Dr. Vincent Yi-Wu Xie to become the new Director of Research and Development.

Dr. Xie brings a lot of experience and credibility to the China Biologic team. Dr. Xie is a veteran in the biopharmaceutical industry and has published several papers and articles related to the field of plasma-based research. He holds a number of patents related to his biopharmaceutical research, including research on plasma-derived hyperimmune globulins and alpha-1 proteinase inhibitor, and has received the Guangzhou City Science and Technology Award in connection with his work “Preparation of Equine Antibodies against Avian Influenza.”

Prior to joining China Biologic, Dr. Xie served from 2007 to 2009 as the General Manager of Research and Development at New a-IKOR Limited, a Hong Kong-based biopharmaceutical company, and from 2002 to 2007, as the Director of Research & Development at Advantek Serum Laboratories Limited, a Hong Kong plasma-based biopharmaceutical company. Dr. Xie has also conducted postdoctoral research in various departments in the University of Hong Kong and the Chinese University of Hong Kong.

When asked about the impact of bringing Dr. Xie into the China Biologic family, Company CEO Chao Ming Zhao was quoted as saying, “We are very pleased to have Dr. Xie join our research team. He brings years of research experience and managerial expertise related to the biopharmaceutical industry to China Biologic Products. We expect that his presence on our team will serve to strengthen our research and development efforts as part of our strategy to bring new higher margin products to market.”

China Biologic has been trading in the $5.60 range and is closing in on a new 52-week high. The company has been consistently releasing positive news and may be a force on Wall Street in the near future.

Let’s hear your thoughts below:

Join the Discussion